Literature DB >> 21666213

Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission.

Jennifer S Rota1, Carole J Hickman, Sun Bae Sowers, Paul A Rota, Sara Mercader, William J Bellini.   

Abstract

In 2009, measles outbreaks in Pennsylvania and Virginia resulted in the exposure and apparent infection of 2 physicians, both of whom had a documented history of vaccination with >2 doses of measles-mumps-rubella vaccine. These physicians were suspected of having been infected with measles after treating patients who subsequently received a diagnosis of measles. The clinical presentation was nonclassical in regard to progression, duration, and severity. It is hypothesized that the 2 physicians mounted vigorous secondary immune responses typified by high avidity measles immunoglobulin G antibody and remarkably high neutralizing titers in response to intense and prolonged exposure to a primary measles case patient. Both of the physicians continued to see patients, because neither considered that they could have measles. Despite surveillance for cases among contacts, including unvaccinated persons, no additional cases were identified. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666213     DOI: 10.1093/infdis/jir098

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  Implication of health care personnel in measles transmission.

Authors:  Núria Torner; Ruben Solano; Cristina Rius; Angela Domínguez; The Measles Elimination Program Surveillance Network Of Catalonia Spain
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

2.  Measles in Healthcare Facilities in the United States During the Postelimination Era, 2001-2014.

Authors:  Amy Parker Fiebelkorn; Susan B Redd; David T Kuhar
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

3.  Seroprevalence and durability of rubella virus antibodies in a highly immunized population.

Authors:  Stephen N Crooke; Iana H Haralambieva; Diane E Grill; Inna G Ovsyannikova; Richard B Kennedy; Gregory A Poland
Journal:  Vaccine       Date:  2019-05-21       Impact factor: 3.641

4.  The Brief Case: Secondary Measles and the Pitfalls of Diagnostic Testing.

Authors:  Marwan M Azar; Joseph Canterino; Marie L Landry
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

5.  Outbreak of measles among persons with secondary vaccine failure, China, 2018.

Authors:  Zhujiazi Zhang; Meng Chen; Rui Ma; Jingbin Pan; Luodan Suo; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

6.  The Clinical Impact and Cost-effectiveness of Measles-Mumps-Rubella Vaccination to Prevent Measles Importations Among International Travelers From the United States.

Authors:  Emily P Hyle; Naomi F Fields; Amy Parker Fiebelkorn; Allison Taylor Walker; Paul Gastañaduy; Sowmya R Rao; Edward T Ryan; Regina C LaRocque; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2019-07-02       Impact factor: 9.079

7.  GUIDELINES FOR THE PREVENTION AND CONTROL OF MEASLES OUTBREAKS IN CANADA: An Advisory Committee Statement (ACS) Measles and Rubella Elimination Working Group (MREWG).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2013-10-30

8.  Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings.

Authors:  Sara Mercader; Philip Garcia; William J Bellini
Journal:  Clin Vaccine Immunol       Date:  2012-09-12

9.  Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.

Authors:  Miguel Ángel Muñoz-Alía; Claude P Muller; Stephen J Russell
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

10.  Epidemiology of two large measles virus outbreaks in Catalonia: what a difference the month of administration of the first dose of vaccine makes.

Authors:  Núria Torner; Andres Anton; Irene Barrabeig; Sara Lafuente; Ignasi Parron; César Arias; Neus Camps; Josep Costa; Ana Martínez; Roser Torra; Pere Godoy; Sofia Minguell; Glòria Ferrús; Carmen Cabezas; Ángela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-09       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.